St. Jude Medical ($STJ) got sideswiped with an FDA safety alert over one of the company's heart plugs based on reports that it could potentially wear away tissue and ...

St. Jude Medical Inc.’s device to plug openings in the heart after a stroke failed to definitively prevent repeat incidents in patients under age 60 compared with non-surgical drug treatment, two ...

AbbottABT recently announced results for its AMPLATZER Amulet left atrial appendage (LAA) occlusion device in a bid to fortify its core Structural Heart business. Data was presented at EuroPCR, the ...

In high-risk patients with nonvalvular atrial fibrillation (A-fib), left atrial appendage (LAA) occlusion using a cardiac plug device can be safely performed and effectively prevents long-term stroke, ...

AGA Medical Inc. (NASDAQ: AGAM) has enrolled the first patient in a clinical trial of a cardiac device aimed at preventing strokes in patients with abnormal heartbeats. CEO John Barr called the first ...

St. Jude Medical is recalling a component of its Amplatzer PFO Occluder--courtesy of St. Jude Medical St. Jude Medical ($STJ) is recalling the device it uses to ...

The risk of thrombus formation after percutaneous left atrial appendage (LAA) occlusion with a plug device is increased in patients with higher CHADS 2 and CHA 2 DS 2-VASc scores and platelet counts, ...

(RTTNews) - Abbott Laboratories (ABT) announced Monday that the U.S. Food and Drug Administration (FDA) approved the company's Amplatzer Amulet Left Atrial Appendage Occluder to treat people with ...